Floatz logo

jsb462

Progressive Metastatic Castrate Resistant Prostate Cancer

Novartis PharmaceuticalsPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

251 Active assets in the Progressive Metastatic Castrate Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

jsb462 is also rated in:

prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Prostatic Cancer, Castration-ResistantDormant
CCC
Indicative ·
53 / 100
View asset →
metastatic prostate carcinomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →